A FLOW CYTOMETRY-BASED LYMPOCYTE TEST FOR IMPROVED DETECT OF BERYLLIUM HYPERSEN

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。慢性铍病是由吸入铍的免疫反应引起的，发生在1%至5%的铍工人人群中。CBD的一个重要特征是对铍过敏。铍超敏反应通常用从外周血中分离的淋巴细胞和胸腺嘧啶掺入进行体外检测。我们开发了一种流式细胞术，用于分析血液淋巴细胞亚群增殖对可溶性铍的反应。该试验称为免疫- lpt（淋巴细胞增殖试验），在同一试验中结合了BrDU摄取或细胞周期分析与免疫表型分析。铍敏感性的主要目标是CD4+细胞群。免疫- lpt已经。已通过诊断为慢性铍病患者的外周血样本得到验证。在与环境安全和健康部门的合作下，免疫- lpt正在被用于筛选LANL铍工人群体和能源部系统中其他铍工人群体对铍的超敏反应。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Chronic Beryllium Disease is caused by an immune response to inhaled beryllium, and occurs in 1 to 5% of the beryllium worker population. A critical feature of CBD is hypersensitivity to beryllium. Beryllium hypersensitivity is typically assayed in vitro using lymphocytes isolated from peripheral blood samples and thymidine incorporation. We have developed a flow cytometry assay for the analysis of blood lymphocyte subset proliferation in response to a challenge with soluble beryllium. The test, called the Immuno-LPT (Lymphocyte Proliferation Test) combines BrDU uptake or cell cycle analysis with immunophenotyping in the same assay. The primary target for beryllium sensitivity is the CD4+ cell population. The Immuno-LPT has been. has been validated using peripheral blood samples from patients diagnosed with Chronic Beryllium Disease. In collaboration with Environmental Safety and Health Division, the Immuno-LPT is being applied to screen the LANL beryllium worker cohort and other beryllium worker cohorts in the DOE system for hypersensitivity to beryllium.